Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Merck KGaA. (11/19/18). "Press Release: Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer [Not intended for US, Canada and UK-based media]". Darmstadt.

Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 Pfizer Inc. (NYSE: PFE)
  Group Pfizer (Group)
Products Product avelumab (MSB0010718C)
  Product 2 clinical research
Index term Index term Pfizer–Merck (DE): antibody cancer drug, 201411– collab dev + commerc of anti-PD-L1 antibody $850m upfront + $2b milestones + shared costs + revenues
Persons Person Boshoff, Chris (Pfizer 201610 Head of Immuno-Oncology, Early Developm + Translational Oncology)
  Person 2 Rossetti, Luciano (Merck (DE) 201407– Global Head RnD at Merck Serono before Merk Sharp & Dohme)
     


   
Record changed: 2018-11-22

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top